OTCPK:LIXT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets.

Risk Analysis

Does not have a meaningful market cap ($60M)



Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has Lixte Biotechnology Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LIXT has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

LIXT

0.7%

US Biotechs

1.0%

US Market


1 Year Return

-18.2%

LIXT

23.6%

US Biotechs

4.1%

US Market

Return vs Industry: LIXT underperformed the US Biotechs industry which returned 22.1% over the past year.

Return vs Market: LIXT underperformed the US Market which returned 3.7% over the past year.


Shareholder returns

LIXTIndustryMarket
7 Day0%0.7%1.0%
30 Day0%4.5%5.4%
90 Day-2.2%11.4%-5.7%
1 Year-18.2%-18.2%24.8%23.6%6.5%4.1%
3 Year275.0%275.0%35.4%30.9%28.3%19.8%
5 Year350.0%350.0%-2.3%-8.2%52.2%35.0%

Price Volatility Vs. Market

How volatile is Lixte Biotechnology Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Lixte Biotechnology Holdings undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Lixte Biotechnology Holdings is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Lixte Biotechnology Holdings has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Lixte Biotechnology Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

31.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lixte Biotechnology Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Lixte Biotechnology Holdings performed over the past 5 years?

3.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LIXT is currently unprofitable.

Growing Profit Margin: LIXT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LIXT is unprofitable, but has reduced losses over the past 5 years at a rate of 3.7% per year.

Accelerating Growth: Unable to compare LIXT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LIXT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: LIXT has a negative Return on Equity (-116.76%), as it is currently unprofitable.


Next Steps

Financial Health

How is Lixte Biotechnology Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: LIXT's short term assets ($2.3M) exceed its short term liabilities ($225.3K).

Long Term Liabilities: LIXT has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: LIXT is debt free.

Reducing Debt: LIXT had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LIXT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if LIXT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Lixte Biotechnology Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LIXT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LIXT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LIXT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LIXT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LIXT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average board tenure


CEO

John Kovach (82yo)

no data

Tenure

US$60,000

Compensation

Dr. John S. Kovach, M.D, founded Lixte Biotechnology Holdings, Inc. in August 2005 and serves as its Chairman, Chief Executive Officer, President, Principal Financial Officer. From 1994 to 2000, Dr. Kovach ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD60.00K) is below average for companies of similar size in the US market ($USD595.62K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
John Kovach
Founderno dataUS$60.00k25.53% $15.4m
Philip Palmedo
Independent Director13.92yrsUS$47.27k1.74% $1.0m
Daniel Von Hoff
Member of Scientific Advisory Committee6.33yrsno datano data
Stephen Forman
Independent Director4yrsUS$47.27k0.18% $110.2k
Iwao Ojima
Member of Scientific Advisory Committeeno datano datano data
Yun Yen
Independent Director1.75yrsUS$47.27kno data
Sze Ho
Independent Director1.75yrsUS$47.27kno data

4.0yrs

Average Tenure

70.5yo

Average Age

Experienced Board: LIXT's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Lixte Biotechnology Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Lixte Biotechnology Holdings, Inc.
  • Ticker: LIXT
  • Exchange: OTCPK
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$60.341m
  • Shares outstanding: 67.05m
  • Website: https://www.lixte.com

Number of Employees


Location

  • Lixte Biotechnology Holdings, Inc.
  • 248 Route 25A, No. 2
  • East Setauket
  • New York
  • 11733
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LIXTOTCPK (Pink Sheets LLC)YesCommon StockUSUSDSep 2007

Biography

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primary focuses on developing various treatments for human cancers and other non-malignant diseases, including vascular diseases, such as heart attacks and strokes, and diabetes, as well as genetic diseases comprising Gaucher’s disease; and depression and post-traumatic stress syndrome. It develops protein phosphatase inhibitors that include LB-100 series of compounds; and histone deacetylase inhibitors, which comprises LB-200 series of compounds for the treatment of cancer, as well as in the prevention and treatment of neurodegenerative diseases, which are under various stages of pre-clinical and clinical developments. The company was founded in 2005 and is based in East Setauket, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/26 02:54
End of Day Share Price2020/05/20 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.